Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-02-24
2010-12-28
Chen, Shin-Lin (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023500, C536S024100
Reexamination Certificate
active
07858368
ABSTRACT:
The present invention relates to recombinant adenoviral vectors bearing exogenous genes that encode for therapeutic proteins useful in the treatment of hepatic cirrhosis and generalized fibrosis, such as renal fibrosis, pulmonary fibrosis, hypertrophic scars and keloid of the skin, and/or in other target organs susceptible to suffer from it. The invention also relates to a mechanism of tissue-specific recognition of the affected cells by means of delivery of therapeutic genes to cirrhotic organs.
REFERENCES:
patent: 5166320 (1992-11-01), Wu et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5756086 (1998-05-01), McClelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5872154 (1999-02-01), Wilson et al.
patent: 5885808 (1999-03-01), Spooner et al.
patent: 5895759 (1999-04-01), Strauss et al.
patent: 5910487 (1999-06-01), Yew et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5980886 (1999-11-01), Kay et al.
patent: 6265212 (2001-07-01), Fallaux et al.
patent: 6436393 (2002-08-01), Bilbao et al.
patent: 6686198 (2004-02-01), Melton et al.
patent: WO 94/28938 (1994-12-01), None
patent: WO 96/18419 (1996-06-01), None
patent: WO 97/09420 (1997-03-01), None
patent: WO 97/17090 (1997-05-01), None
patent: WO 97/40157 (1997-10-01), None
patent: WO 98/46780 (1998-10-01), None
patent: WO 98/48024 (1998-10-01), None
Thomas et al., 2003, Nature Reviews/ Genetics, vol. 4, p. 346-358.
Fernandez et al., 1998, Surgery, vol. 124, p. 129-136.
Baker et al., 1996, Matrix Biology, vol. 15, pp. 383-395.
Hasty et al., 1990, The Journal of Biological Chemistry, vol. 265, No. 20, pp. 11421-11424.
Gros et al., 1997, Human Gene Therapy, vol. 8, No. 18, p. 2249-2259.
P. P. Anthony, K. G. Hishack, N. C. Nayak, H. E. Poulsen, P. J. Scheuer, L. H. Sobin; “The Morphology of Cirrhosis: Definition, Nomenclature and Classification”,Bulletin of the World Health Organization; 1977; 55:521-540.
J. Armendariz-Borunda and M. Rojkind; “A Simple Quantitative Method for Collagen Typing in Tissue Samples: Its Application to Human Liver with Schistosomiasis”;Collagen Rel. Res. 1984, vol. 4, 35-47.
J. Armendariz-Borunda, K. Katayama and J. M. Seyer; “Transcriptional Mechanisms of Type I Collagen Gene Expression are Differentially Regulated by Interleukin-1β, Tumor Necrosis Factor α, and Transforming Growth Factor β in Ito Cells”;J. Biol. Chem. 267:14316-14321; 1992.
Verma et al., 1997, Nature, vol. 389, pp. 239-242.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill NY p. 77-101.
Gorecki, 2001, Expert Opin. Emerging Drigs, 6(2): 187-198.
Carmeliet et al., 1997, Blood, vol. 4, pp. 1527-1534.
Ludin et al., 1996, Gene, vol. 173, p. 07-111.
Lu et al., 1998, Gene Therapy, vol. 5, pp. 888-895.
J. Armendariz-Borunda, H. Katai, C. M. Jones, J. M. Seyer, A. H. Kang, and R. Raghow; “Transforming Growth Factor β Gene Expression is Transiently Enhanced at a Critical Stage during Liver Regeneration Following CC14Treatment”;Laboratory Investigation; 69:283-294, 1993.
J. Armendariz-Borunda, C. Simkevich, N. Roy, R. Raghow, A. H. Kang and J. M. Seyer , “Activation of Ito Cells Involves Regulation of AP-1 Collagen Gene Expression”;Biochemical Journal304:817-824, 1994.
C. Chen and H. Okayama; “Calcium Phosphate-Mediated Gene Transfer: a Highly Efficient Transfection System for Stably Transforming Cells with Plasmidic DNA”,Biotechniques1988, 6:632-638.
J.T. Douglas and D. T. Curiel, “Adenoviruses as Vectors for Gene Therapy”,Science and Medicine, Mar./Apr. 1997, 44-53.
R. Dumaswala, D. Berkowitz and J. E. Heubi, “Adaptive Response of the Enterohepatic Circulation of Bile Acids to Extrahepatic Cholestiasis”, Hepatology 1996, vol. 23, No. 3: 623-629.
Scott L. Friedman, “The Cellular Basis of Hepatic Fibrosis: Mechanisms and Treatment Strategies”,The New England Journal of Medicine1993, vol. 328, No. 25:1828-1835.
F.L. Graham and A. J. Van Der Eb, “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA”,Virology1973, 52:456-467.
Tong-Chuan He, Shibin Zhou, Luis T. Da Costa, Kian Yu, Kenneth W. Kinzler and Bert Vogelstein, “A Simplified System for Generating Recombinant Adenoviruses”,Proc. Natl. Acad. Sci. USA, vol. 95: 2509-2514, Mar. 1998.
S. Lee, C. Girod, A. Draillon, A. Hadengue, and D. Lebec, “Hemodynamic Characterization of Chronic Bile Duct-Ligated Rats: Effect of Pentobarbital Sodium”,AM Journal Fisiol. 1986; 251:176-180.
Marie-Jeanne T. F. D. Vrancken Peeters, A. Lieber, J. Perkins, and M. A. Kay; “Methods for Multiple Portal Vein Infusion in Mice: Quantitation of Adenovirus-Mediated Hepatic Gene Transfer”;BioTechniquesFeb. 1996; 20:278-285.
F. Mion, A. Geloen, E. Agosto and Y. Minaire, “Carbon Tetrachloride Induced Cirrhosis in Rats: Influence of the Acute Effects of the Toxin on Glucose Metabolism”,Hepatology1996, vol. 23, No. 2:582-587.
S. Nakano, J. Haratake, and H. Hashimoto, “Alteration in Bile Ducts and Peribiliary Microcirculation in Rats After Common Bile Duct Ligation”;Hepatology, 1995, vol. 21, No. 5, 1380-1386.
J. L. Poo, A. Estanes, J. Pedraza-Chaverri, C. Cruz, C. Perez, A. Huberman and M. Uribe; “Cronologia de Hipertension Portal, Disminucion de Excrecion de sodio y activacion del sistema renina-angiotensina en cirrosis biliar experimental”, Rev.,Invest Clin., 49:15-23, 1997.
A. Rojas-Martinez, P. R. Wyde, C. A. Montgomery, S. H. Chen, S. L. C. Woo, and E. Auilar-Cordova; “Distribution, Persistency, Toxicity and Lack of Replication of an El A-Deficient Adenoviral Vector after Intracardiac Delivery in the Cotton Rat”;Cancer Gene Ther., vol. 5, 1998, pp. 365-370.
S. Shimohama, M. B. Rosenberg, A. M. Fagan, J. A. Wolff, M. P. Short, X. O. Breakefield, T. Friedmann, and F. H. Gage, “Grafting Genetically Modified Cells into the Rat Brain: Characteristics ofE. coliβ-Galactosidase as a Reporter Gene”;Molecular Brain Res. 5:271-278; 1989.
D. J. Weiss, D. Liggitt and J. G. Clark, “In Situ Histochemical Detection of β-Galactosidase Activity in Lung: Assessment of X-Gal Reagent in DistinguishedlacZGene Expression and Endogenous β-Galactosidase Activty”,Human Gene Therapy, Sep. 1, 1997; 8:1545-1554.
M. A. Zern and T. F. Kresina, “Hepatic Drug Delivery and Gene Therapy”,Hepatology, 1997, vol. 25, No. 2, 484-491.
G. Zhu, A. G. Nicolson, X. Zheng, T. B. Strom and V. P. Sukhatme; “Adenovirus-Mediated β-Galactosidase Gene Delivery to the Liver Leads to Protein Deposition in Kidney Glomeruli”;Kidney International; 1997, vol. 52, 992-999.
Armendariz-Borunda, J., et al.: “Regulation of TGF Gene Expression in Rat Liver Intoxicated with Carbon Tetracholirde”, FASEB J., vol. 4, pp. 215-221, 1990.
Arthur, M. J. P.,: Collagenases and Liver Fibrosis:, J. Hepatology, vol. 22, pp. 43-48, 1995.
Bradford, M. M.: “A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding”, Anal. Biochem., vol. 72, pp. 248-254, 1976.
Bramson, J. L., et al.: “The Use of Adenoviral Vectors for Gene Therapy and Gene Transfer In Vivo”, Current Opinion in Biotechnology, vol. 6, pp. 590-595, 1995.
Brann, T., et al.: “Adenoviral Vector-Mediated Expression of Physiologic Levels of Human Factor Viii Nonhuman Primates”, Hum. Gene Ther., vol. 10, pp. 2999-3011, 1999.
Corcoran, M. L., et al.:
Aguilar Cordova Estuardo
Armendariz Borunda Juan
Chen Shin-Lin
Morgan & Lewis & Bockius, LLP
TGT Laboratories, S.A. DE C.V.
LandOfFree
Recombinant adenoviral vectors and their utility in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant adenoviral vectors and their utility in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adenoviral vectors and their utility in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173020